In Q1'26, SG&A Expenses for CVS register at $0, indicating no data available for this period, while R&D Expenses remain consistently at $0 across all quarters. Total operating expenses are thus solely driven by SG&A in prior periods, with the latest reported value at $11.46B in Q4'25. From Q2'23 to Q4'25, SG&A Expenses exhibit a steady upward trend, increasing from $9.87B to $11.46B, reflecting consistent growth in administrative and selling costs amid stable operations. R&D Expenses show no activity throughout the period from Q2'23 to Q1'26, suggesting minimal investment in research and development, with total operating expenses following the SG&A trajectory without significant volatility or inflection points.